Ozone Pharmaceuticals recently launched a new division AdLife; Currently in the inception stages

Research has shown 37.5 million couples who are actively seeking children suffer from infertility. It is estimated that while female factor accounts for 40-50% of infertility among couples, infertility attributable to male factors is on the rise and constitutes 30-40% of infertility.

Infertility, the inability to conceive by natural means, is a medical condition with high prevalence affecting nearly 15- 20% of married couples in India.

Moreover, to address the rising concern of infertility through medical sciences, is also seen in the increase of experts in this field. Earlier, there was a scarcity of skilled IVF specialists and embryologists in India, which was with only about 3-4% (700-1,000) of the pool of gynaecologists in 2015 performing IVF procedures but it has increased to >10% during from the universe of gynaecologists during 2020.  There is an urgent need to address the skill gap and technical expertise  required to provide high quality treatment towards improving outcomes and patient safety.

Similarly, there is also a need of addressing the significant geographical skew in the distribution of infertility centres with ~55% of IVF cycles being performed in the top eight metro cities coupled with a highly fragmented market is affecting access to quality treatment. This is also followed by Absence of a regulatory framework for quality management of ART centres and patient safety resulting in mushrooming of IVF clinics with poor treatment outcomes and quality of patient care. Overall, low awareness of fertility problems is observed among couples despite the high need for parenthood and the importance of    social status associated with parenthood.

Ozone’s AdLife will be pioneering the distribution of IVF access to more areas in India. By being present with quality IVF support treatments and promising high clinical outcomes, Ozone Pharmaceuticals’ AdLife will be aiming revolutionise, spread awareness for as well as advance the infertility therapy area.

If you have any objection to this press release content, kindly contact pr.error.rectification@gmail.com to notify us. We will respond and rectify the situation in the next 24 hours.